Pengobatan Kanker Tingkat Lanjut
Melampaui Batas
Kami menghubungkan Anda dengan 3 rumah sakit kanker TERBAIK di Tiongkok dan AS. Medebound HEALTH telah berdiri selama lebih dari 10 tahun, dengan lebih dari 3.000 kasus sukses. Pelajari LEBIH LANJUT tentang Medebound HEALTH.
50+
RUMAH SAKIT MITRA
30+
JENIS KANKER YANG DIOBATI
10+
TAHUN BERBISNIS
24/7
DUKUNGAN YANG DEDIKASI
Medebound HEALTH
AS SEEN IN
Sebuah Batasan Baru dalam
Keunggulan Onkologi Tiongkok
Before Medebound HEALTH
CAR-T feels out of reach — the US price makes it impossible
Hours of research, dead ends, more questions than answers
Worried about going abroad — language, hospitals, being misled
Carrying the weight of this decision completely alone
After Medebound HEALTH
A clear, honest assessment of whether CAR-T in China is right for you
Matched with a JCI-accredited hospital with 2,000+ CAR-T cases
Every detail handled — visa, travel, translation, follow-up
Your family focused entirely on one thing: healing
Medebound HEALTH, our parent company headquartered in New York, brings nearly 10 years of experience in cross-border second opinions and medical concierge services, primarily connecting international patients with advanced care in the U.S. Building on that foundation, ChinaCureLink was established to help international families access advanced treatment options in China, including CAR-T therapy.
Our physician-founded and physician-led team includes a Harvard physician, a former president of New York Medical College, and other distinguished academic medical leaders.
ChinaCureLink goes beyond traditional medical coordination. Our team combines medical knowledge, cross-border healthcare expertise, and practical patient-navigation experience to help families understand their options, evaluate which treatment pathway and medical center may be most appropriate, and make better-informed decisions before committing to treatment or international travel. Once a pathway is chosen, we provide end-to-end support—from medical evaluation and hospital access to treatment coordination and on-the-ground assistance in China.
MENGAPA TIONGKOK
Sebuah Batasan Baru dalam
China telah menginvestasikan miliaran dolar dalam infrastruktur penelitian dan pengobatan kanker, memposisikan dirinya sebagai pemimpin global dalam inovasi onkologi.
01
Penelitian Perintis
China menerbitkan lebih banyak makalah penelitian onkologi daripada negara mana pun. Rumah sakit terkemuka menjalankan ratusan uji klinis, memberikan pasien akses ke terapi yang belum tersedia di Barat.
03
Infrastruktur Medis Elit
Rumah sakit papan atas seperti Peking Union dan Fudan University Cancer Center mampu bersaing dengan institusi mana pun di dunia, dengan departemen onkologi yang terakreditasi JCI.
04
Keunggulan Biaya yang Dramatis
Perawatan dengan kualitas yang sama di China harganya 40–70% lebih murah daripada di AS, Inggris, atau Australia — tanpa mengorbankan hasil atau standar perawatan.
05
Onkologi Integratif
China secara unik memadukan onkologi Barat berbasis bukti dengan Pengobatan Tradisional Tiongkok — ramuan herbal, akupunktur, dan qigong untuk meningkatkan toleransi pengobatan dan kualitas hidup.
06
Koordinasi Ujung-ke-Ujung
Oncologists who perform CAR-T regularly, with thousands of cases behind them.
Perawatan Komprehensif
You are not settling for second best
The same class of therapy as the US, at hospitals with thousands of cases, for a fraction of the cost.
Time is not working against you
With manufacturing as fast as 1-2 weeks, your loved one spends less time waiting and more time in treatment.
Cost is no longer the reason you say no
At up to 70% less than US pricing, CAR-T in China puts a treatment you thought was out of reach back within reach.
You will never be lost in the system
Every step is coordinated by a team that has guided 3,000+ patients through international care before you.
You can focus on your loved one
Not on visas, translators, hospitals, or logistics. We handle all of it.
Perawatan Komprehensif
Jenis Kanker yang Kita
Spesialisasi dalam
At 76, William was diagnosed with MEITL, a rare and aggressive intestinal lymphoma — and the targeted drug his biology responded to wasn't approved in Canada for his condition. Rather than stop at chemotherapy, his family sought a second opinion from specialists in Beijing. What came back was a detailed, stage-by-stage treatment roadmap his local team couldn't offer.
After nearly a decade of multiple myeloma relapsing again and again, Elena Rossi had exhausted the treatment options available to her in Europe. Her search led her to a clinical trial in Beijing for BCMA-targeted CAR-T therapy — a treatment not yet available at home. See how she became the 700th patient in one of China's most active CAR-T programs.
Perjalanan Anda ke
Dari kontak pertama hingga janji temu pertama Anda di Tiongkok, kami menangani setiap detail dengan penuh kebijaksanaan dan keahlian.
1
2
3
4
5
Konsultasi Gratis
Bicaralah dengan koordinator medis kami. Bagikan diagnosis, catatan medis, dan pertanyaan Anda — tanpa kewajiban apa pun.
Tinjauan Kasus
Tim klinis kami akan meninjau kasus Anda dan mengidentifikasi rumah sakit dan spesialis yang paling sesuai.
Rencana Perawatan
Dapatkan proposal terperinci: rumah sakit yang direkomendasikan, spesialis, protokol perawatan, jangka waktu, dan perkiraan biaya.
Perjalanan & Logistik
Kami mengurus visa medis, penerbangan, akomodasi, dan transportasi di dalam negeri — layanan sepenuhnya personal.
Perawatan & Dukungan
Koordinator dan penerjemah khusus Anda akan menemani Anda selama setiap janji temu dan prosedur.
Suara-suara dari
Harapan
Frequently Asked Questions
HUBUNGI KAMI
Mulailah
Percakapan
Koordinator medis kami akan merespons dalam waktu 24 jam. Semua komunikasi bersifat sangat rahasia.
📧
💬
WHATSAPP / WECHAT
+1 (800) CHINACURE
🌏
KANTOR
Beijing · Shanghai · Singapura · New York
⚕ ChinaCure adalah layanan fasilitasi wisata medis dan tidak memberikan nasihat medis secara langsung. Semua keputusan pengobatan dibuat oleh dokter yang berkualifikasi di lembaga mitra kami. Informasi yang dibagikan dijaga kerahasiaannya secara ketat.